DLL3 in Focus: Applying the Latest Evidence to Optimize Patient Outcomes in SCLC and LCNEC-L

ASCO 2026 Virtually Live Satellite Symposium

Monday, June 1, 2026

5:00 PM – 6:30 PM PT
6:00 PM – 7:30 PM MT
7:00 PM – 8:30 PM CT
8:00 PM – 9:30 PM ET

Program Overview

This educational program is designed to enhance the knowledge and competence of healthcare professionals caring for patients with neuroendocrine lung cancers. It provides an overview of DLL3 biology in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma of the lung (LCNEC-L), the scientific rationale supporting DLL3 as a target for bispecific T-cell engager (BiTE) therapies, and the mechanism by which these agents redirect T cells. The program also reviews emerging clinical evidence on the efficacy, safety, and dosing of DLL3-targeted BiTEs in extensive-stage SCLC (ES-SCLC) and LCNEC-L, while equipping participants with practical strategies to prevent and manage treatment-related adverse events (TRAEs).

Target Audience

This activity is designed to meet the educational needs of oncologists and oncology advanced practice practitioners (APPs).

Learning Objectives

Upon the completion of this program, attendees should be able to:

Identify the prevalence of DLL3 overexpression in SCLC and LCNEC-L, the rationale for its suitability as a target for T-cell recognition, and the mechanism of action of DLL3-targeting BiTEs
Summarize clinical trial efficacy and safety data and recommended dosing for BiTEs that target DLL3 in ES-SCLC and LCNEC-L
Implement strategies for preventing and mitigating TRAEs

Joint Accreditation Statement

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement

Med Learning Group designates this virtually live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

AAPA Credit Designation Statement – Live

Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ACCME Innovation Partner

Nurses (ANCC) Credit Designation

Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Disclosure of Relevant Financial Relationships

Faculty Member	Disclosures
Aman Chauhan, MD	Dr. Chauhan discloses that he receives consulting fees from Boehringer Ingelheim, Curium, Exelixis, Novartis, Ipsen, Tersera, Sanofi and Crenetics. He owns stocks, stock options or other ownership interest excluding diversified mutual funds in Kura, Revolution Med and Elicio.
Daniel Morgensztern, MD	Dr. Morgensztern discloses that he receives consulting fees from Bristol Myers Squibb, AbbVie, Tubulis, Natera, Johnson & Johnson, Bayer, and Lilly. He receives research funds from Merck, Celgene, AstraZeneca, Incite, AbbVie, Bristol Myers Squibb, Pfizer, EpicentRx, and Lilly

All relevant financial relationships have been mitigated.

Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
Shannon Mutch MS, RN, OCN, has nothing to disclose.
M. Susan Burke, MD, has nothing to disclose.
A medical reviewer from CME Peer Review LLC, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Carrie Allen, PharmD, BCPS, Medical Director for Med Learning Group, has nothing to disclose.
Andi Koral, MS, CMP-HC, Program Manager for Med Learning Group, has nothing to disclose.

Disclosure Of Unlabeled Use

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

Method of Participation

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

Disclaimer

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Med Learning Group

This activity is provided by Med Learning Group.

This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Release date: June 1, 2026
Expiration date: June 1, 2027
Estimated time to completion: 1.5 hours